Triptorelin

From Wikipedia, the free encyclopedia

Template:Short description Template:DMCA Template:Cs1 config Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Triptorelin
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
Trade namesDecapeptyl, others
AHFS/Drugs.comMicromedex Detailed Consumer Information
License dataPage Template:Plainlist/styles.css has no content.
Routes of
administration		Intramuscular
Drug classGnRH analogue; GnRH agonist; Antigonadotropin
ATC codePage Template:Plainlist/styles.css has no content.
Legal status
Legal statusPage Template:Plainlist/styles.css has no content.
Pharmacokinetic data
Elimination half-lifeThe elimination half-life for patients with hepatic impairment was similar to that of patients with renal impairment (geometric mean t(1/2, z): 6.6 h, 7.7 h and 7.6 h for Groups II, III and IV, respectively), but significantly longer than in healthy volunteers (2.8 h for Group I)

[3]

Triptorelin is a gonadotropin-releasing hormone (GnRH) analogue with enhanced affinity for GnRH receptors and a prolonged half-life due to its resistance to enzymatic degradation.
ExcretionKidney
Identifiers
  • 5-oxo-D-prolyl-L-histidyl-Ltryptophyl-L-seryl-Ltyrosyl-3-(1H-indol-2-yl)-L-alanylleucyl-L-arginyl-L-prolylglycinamide
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC64H82N18O13
Molar mass1311.473 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
  • CC(C)C[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](Cc2c[nH]c3c2cccc3)NC(=O)[C@H](Cc4ccc(cc4)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc5c[nH]c6c5cccc6)NC(=O)[C@H](Cc7cnc[nH]7)NC(=O)[C@@H]8CCC(=O)N8
  • InChI=1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)/t44-,45-,46-,47-,48+,49-,50-,51-,52-/m0/s1 ☒N
  • Key:VXKHXGOKWPXYNA-PGBVPBMZSA-N ☒N
Data page
Template:Infobox drug/data page link
Page Template:Nobold/styles.css has no content. ☒NcheckY (what is this?)Page Template:Nobold/styles.css has no content.  (verify)

Triptorelin, sold under the brand name Decapeptyl among others, is a medication that acts as an agonist analog of gonadotropin-releasing hormone, repressing expression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).[4][5] It was patented in 1975 and approved for medical use in 1986.[6] Triptorelin is a therapeutic alternative on the World Health Organization's List of Essential Medicines.[7]

It is a decapeptide (pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2) and a gonadotropin-releasing hormone agonist (GnRH agonist) used as the acetate or pamoate salts.

Primary indications include endometriosis,[8] for the reduction of uterine fibroids, to treat prostate cancer, to treat male hypersexuality with severe sexual deviation[5], and to delay puberty in cases of precocious puberty or gender dysphoria.[9]


Medical uses

Script error: No such module "Labelled list hatnote".Triptorelin is used to treat prostate cancer as part of androgen deprivation therapy.[10]

Another common use in the United Kingdom is for hormone replacement therapy to suppress testosterone or estrogen levels in transgender people (in conjunction with estradiol valerate for trans women or testosterone for trans men). Spironolactone and cyproterone acetate are other drugs used by trans people to suppress sex hormones, but these drugs have a completely different mechanism of action.[11] It can also be used as a puberty blocker[12] in the case of precocious puberty.[10]

Triptorelin has been used as a chemical castration agent for reducing sexual urges in sex offenders.[13]

Drug action

Triptorelin is a gonadorelin analogue, also known as luteinizing hormone releasing analogue (GnRH analogue, LHRH analogue).[4] The drug binds to receptors in the pituitary gland and stimulates secretion of gonadotropins (namely luteinizing hormone LH and follicle-stimulating hormone FSH). This causes an initial phase of LH and FSH stimulation, prior to down-regulation of the gonadotrophin-releasing hormone receptors, thereby reducing the release of gonadotropins in the long term, which in turn leads to the inhibition of androgen and estrogen production.[5]

Side-effects

General side effects can include:[5]

  • Anaphylaxis
  • Arthralgia
  • Asthenia
  • Asthma
  • Breast tenderness (males and females)
  • Changes in blood pressure
  • Changes in breast size
  • Depression
  • Ovarian cysts
  • Mood changes
  • Skin rashes
  • Hot flashes
  • Weight changes

Society and culture

Brand names

Triptorelin is marketed under the brand names Decapeptyl (Ipsen) for treating prostate cancer, endometriosis, uterine myomas, and precocious puberty,[14] and Diphereline and Gonapeptyl (Ferring Pharmaceuticals).[15] In the United States, it is sold by Watson Pharmaceuticals as Trelstar [16] and by Arbor Pharmaceuticals as Triptodur (an extended-release 6-month depot injection).[17] In Iran, triptorelin is marketed under the brand name Variopeptyl. In the UK and Germany, it is sold as Salvacyl for the treatment of sexual deviations.[18]

History

Triptorelin was developed in Andrew V. Schally's lab at Tulane University.[19] Debiopharm licensed the drug from Tulane in 1982.[20]

Research

Triptorelin and other antiandrogens may be effective in the treatment of obsessive–compulsive disorder.[21]

Dosage in IVF treatment

Minimal daily dose of triptorelin acetate needed to suppress a premature LH surge during IVF treatment has been determined to be 15 microgram daily, and that 50 microg is equivalent to 100 microg in terms of IVF results.[22]

GnRHa doses used in IVF are derived from treatment

schedules used in disseminated prostate cancer, which aim at

complete gonadal suppression under all circumstances. Some

comparative studies indicate that the daily dose of agonist

used in IVF may be decreased without compromising the

results

The interval between initiation of study medication and start of FSH stimulation was defined as the desensitization phase.

For both parameters, adjacent comparisons showed a statistically significant difference between the effect of placebo and 15 μgtriptorelin, but not between 15 and 50 μg, or between 50 and 100 μg (Table II).

moreover, it appeared that a daily dose of 50 μg triptorelincreates a state of pituitary desensitization comparable with the "standard" dose of 100 μg, and this endocrine finding was confirmed in the current study.

In prostate cancer

Modern assay technologies reveal that bilateral orchiectomy results in a serum T level of approximately 15 ng/dL as compared to the historical definition of castration of T < 50 ng/dL

Pharmacokinetics

Gonapeptyl Depot 3.75 mg

The systemic bioavailability of the active component triptorelin from the intramuscular depot is 38.3% in the first 13 days (2.9% per day). Further release is linear at 0.92% of the dose per day on average (34μg). Bioavailability after S.C. application is 69% of I.M. availability.

Plasma triptorelin values decreased to approx. 100 pg/ml before the next application after I.M. or S.C. application (median values).

References

Page Template:Reflist/styles.css has no content.

  1. ^ Page Module:Citation/CS1/styles.css has no content."Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  2. ^ Page Module:Citation/CS1/styles.css has no content."Triptodur- triptorelin kit". DailyMed. U.S. National Library of Medicine. 28 April 2022. Retrieved 15 May 2022.
  3. ^ Page Module:Citation/CS1/styles.css has no content.Müller FO, Terblanchè J, Schall R, van Zyl Smit R, Tucker T, Marais K, et al. (October 1997). "Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency". British Journal of Clinical Pharmacology. 44 (4): 335–341. doi:10.1046/j.1365-2125.1997.t01-1-00592.x. PMC 2042859. PMID 9354307.
  4. ^ a b Page Module:Citation/CS1/styles.css has no content."gonadorelin analogue". Encyclopedia.com. Retrieved 21 September 2019.
  5. ^ a b c d Page Module:Citation/CS1/styles.css has no content.Joint Formulary Committee (2018). British National Formulary (BNF) 70. London: Pharmaceutical Press. p. 635. ISBN 978-0-85711-173-9.
  6. ^ Page Module:Citation/CS1/styles.css has no content.Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 514. ISBN 978-3-527-60749-5.
  7. ^ Page Module:Citation/CS1/styles.css has no content.World Health Organization (2025). The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. Geneva: World Health Organization. hdl:10665/382243.
  8. ^ Page Module:Citation/CS1/styles.css has no content.Leone Roberti Maggiore U, Scala C, Remorgida V, Venturini PL, Del Deo F, Torella M, et al. (June 2014). "Triptorelin for the treatment of endometriosis". Expert Opinion on Pharmacotherapy. 15 (8). Informa Healthcare: 1153–1179. doi:10.1517/14656566.2014.916279. PMID 24832495. S2CID 23843087.
  9. ^ Page Module:Citation/CS1/styles.css has no content.Cohen D, Barnes H (September 2019). "Gender dysphoria in children: puberty blockers study draws further criticism". BMJ. 366 l5647. doi:10.1136/bmj.l5647. PMID 31540909. S2CID 202711942.
  10. ^ a b Page Module:Citation/CS1/styles.css has no content."triptorelin (Intramuscular route)". Drugs.com. Retrieved 11 November 2016.
  11. ^ Page Module:Citation/CS1/styles.css has no content.Wylie KR, Fung Jr R, Boshier C, Rotchell M (2009). "Recommendations of endocrine treatment for patients with gender dysphoria". Sexual and Relationship Therapy. 24 (2): 175–187. doi:10.1080/14681990903023306. S2CID 20471537.
  12. ^ Page Module:Citation/CS1/styles.css has no content.Shumer DE, Nokoff NJ, Spack NP (August 2016). "Advances in the Care of Transgender Children and Adolescents". Advances in Pediatrics. 63 (1): 79–102. doi:10.1016/j.yapd.2016.04.018. PMC 4955762. PMID 27426896.
  13. ^ Page Module:Citation/CS1/styles.css has no content."Study: Drug effectively treats pedophilia". CNN. 11 February 1998. Archived from the original on 11 July 2021. Retrieved 8 July 2018.
  14. ^ Page Module:Citation/CS1/styles.css has no content."Decapeptyl SR 11.25mg (triptorelin pamoate) - Patient Information Leaflet (PIL) - (emc)". www.medicines.org.uk. Retrieved 14 November 2022.
  15. ^ Page Module:Citation/CS1/styles.css has no content."Gonapeptyl Depot 3.75 mg - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Retrieved 14 November 2022.
  16. ^ Page Module:Citation/CS1/styles.css has no content."Trelstar intramuscular: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing". WebMD. Retrieved 14 November 2022.
  17. ^ Page Module:Citation/CS1/styles.css has no content."Triptodur Intramuscular: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing". WebMD. Retrieved 14 November 2022.
  18. ^ Page Module:Citation/CS1/styles.css has no content."Salvacyl, developed by Debiopharm, is launched in two European countries - a new therapeutic avenue for the treatment of sexual deviations". Debiopharm. 23 June 2009. Retrieved 14 November 2022.
  19. ^ Page Module:Citation/CS1/styles.css has no content."About Us – Technology Transfer at Tulane University". Tulane University. Retrieved 4 January 2024.
  20. ^ Page Module:Citation/CS1/styles.css has no content."Dr. Reddy's Launches Debiopharm's Pamorelin LA in India for the Treatment of Locally Advanced or Metastatic, Hormone-Dependent Prostate Cancer". Fierce Pharma. 7 December 2012. Retrieved 4 January 2024.
  21. ^ Page Module:Citation/CS1/styles.css has no content.Nomani H, Mohammadpour AH, Moallem SM, YazdanAbad MJ, Barreto GE, Sahebkar A (December 2019). "Anti-Androgen Drugs in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review". Current Medicinal Chemistry. 27 (40): 6825–6836. doi:10.2174/0929867326666191209142209. PMID 31814547. S2CID 208956450.
  22. ^ Page Module:Citation/CS1/styles.css has no content.Janssens RM, Lambalk CB, Vermeiden JP, Schats R, Bernards JM, Rekers-Mombarg LT, et al. (November 2000). "Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study". Human Reproduction. 15 (11): 2333–2340. doi:10.1093/humrep/15.11.2333. PMID 11056128.

Further reading

Page Template:Refbegin/styles.css has no content.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.

Template:GnRH and gonadotropin receptor modulators Lua error in mw.title.lua at line 404: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal').

Retrieved from "https://cosmopedia.co/index.php?title=Triptorelin&oldid=1653630"